Europe Cancer Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)

The Europe Cancer Therapeutics Market has been segmented by Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy, and Other Therapy Types), Cancer Type, End User, and Geography

Market Snapshot

Image 1
Study Period:

2016-2024

Base Year:

2018

Key Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

The propelling factors for the growth of the European cancer therapeutics market include the ease in regulatory approval for novel cancer therapy in Europe, increase in healthcare spending for cancer, rising prevalence of cancer, and strong R&D initiatives from key players.

The increasing cancer among the population represents the second most important cause of death and morbidity in Europe, accounting for 1.9 million deaths every year. According to WHO, Europe comprises only one-eighth of the total world population, but has around one-quarter of the total global cancer cases. Around 3.7 million new patients are being reported every year in Europe. There are also other factors attributed to the rising incidence of cancer in Europe, i.e. unhealthy lifestyles and inappropriate diet, obesity, and lack of physical activity. Thus, the growing incidence and prevalence of cancer is likely to drive the growth of the cancer therapeutics market in Europe during the forecast period.

The direct cost of cancer has also increased, and thus the cost of cancer drugs as a share of direct health costs has doubled. The increase in the cost of the cancer treatment, along with the drugs prices, has resulted in the growth of the overall market.

In addition, the heavy investments made in R&D activities have enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence have boosted the market growth.

Scope of the Report

As per the scope of the report, cancer therapeutics are drugs that block the growth and proliferation of cancer, by interfering with specific molecules, such as DNA or proteins, which are involved in the growth or expansion of cancerous cells.

By Treatment Type
Chemotherapy
Target Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Other Treatment Types
By Cancer Type
Blood Cancer
Breast Cancer
Prostate Cancer
Gastrointestinal Cancer
Gynecologic Cancer
Respiratory/Lung Cancer
Other Cancer Types
By End User
Hospitals
Specilty Clinics
Cancer and Radiation Therapy Centers
Geography
Europe
Germany
UK
France
Italy
Spain
Rest of Europe

Report scope can be customized per your requirements. Click here.

Key Market Trends

Target Therapy is the Largest Growing Segment under Therapy Type During the Forecast Period

The major factors driving the growth of the target therapy segment is the increase in R&D and the rising prevalence of various types of cancers. Targeted therapy is also gaining importance due to its specificity toward cancer cells, while sparing the toxicity to off-target cells. Thus, owing to the rising approval from regulatory bodies and an increase in the prevalence of all types of cancer, the segment is expected to witness a high growth rate over the forecast period.

Immunotherapies/biologics are also emerging as potential therapies to find a permanent cure for various cancer types among various cancer therapeutics.

Image 2

To understand key trends, Download Sample Report

Competitive Landscape

There are several big pharmaceutical companies present in the market that have started programs to help patients who are suffering from chronic diseases. Thus, there are many hospitals that are found collaborating with the pharmaceutical companies for the treatment and therapy of cancer. With such collaborations, the pharmaceutical companies are able to engage in larger studies that are aimed to speed up the pace of discovery of cancer therapeutics.

Major Players

  1. Amgen Inc.
  2. AstraZeneca PLC
  3. Bayer AG
  4. Bristol-Meyrs Squibb Company
  5. F. Hoffmann-La Roche Ltd

* Complete list of players covered available in the table of contents below

Image 3

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Ease in Regulatory Approval for Novel Cancer Therapy in Europe

      2. 4.2.2 Increase in Healthcare Spending for Cancer

      3. 4.2.3 Rising Prevalence of Cancer in Europe

      4. 4.2.4 Strong R&D Initiatives from Key Players

    3. 4.3 Market Restraints

      1. 4.3.1 Inequality in Access of Cancer Therapy across Europe

      2. 4.3.2 High Cost of Cancer Therapies

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Treatment Type

      1. 5.1.1 Chemotherapy

      2. 5.1.2 Target Therapy

      3. 5.1.3 Immunotherapy (Biologic Therapy)

      4. 5.1.4 Hormonal Therapy

      5. 5.1.5 Other Treatment Types

    2. 5.2 By Cancer Type

      1. 5.2.1 Blood Cancer

      2. 5.2.2 Breast Cancer

      3. 5.2.3 Prostate Cancer

      4. 5.2.4 Gastrointestinal Cancer

      5. 5.2.5 Gynecologic Cancer

      6. 5.2.6 Respiratory/Lung Cancer

      7. 5.2.7 Other Cancer Types

    3. 5.3 By End User

      1. 5.3.1 Hospitals

      2. 5.3.2 Specilty Clinics

      3. 5.3.3 Cancer and Radiation Therapy Centers

    4. 5.4 Geography

      1. 5.4.1 Europe

        1. 5.4.1.1 Germany

        2. 5.4.1.2 UK

        3. 5.4.1.3 France

        4. 5.4.1.4 Italy

        5. 5.4.1.5 Spain

        6. 5.4.1.6 Rest of Europe

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Amgen Inc.

      2. 6.1.2 AstraZeneca PLC

      3. 6.1.3 Bayer AG

      4. 6.1.4 Bristol-Meyrs Squibb Company

      5. 6.1.5 F. Hoffmann-La Roche Ltd

      6. 6.1.6 GlaxoSmithKline PLC

      7. 6.1.7 Johnson & Johnson

      8. 6.1.8 Merck & Co. Inc.

      9. 6.1.9 Novartis AG

      10. 6.1.10 Pfizer Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape Covers- Business Overview, Financials, Products and Strategies, and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please Enter a Valid Message!


Complete your payment details below

Shipping & Billing Information

Payment Information